Healthwire Bureau
New Delhi, January 27: Leading Pharma firm Lupin on Monday said the UK’s regulator Medicines and Healthcare products Regulatory Agency (MHRA) has completed the inspection at its three manufacturing plants in the country.
The inspection of the three units at Pithampur closed with no critical observation and one major observation, the pharma major said in a filing to BSE.
“We are pleased with the outcome of the inspection by the UK MHRA. It is a meaningful development for our Pithampur facilities. We uphold the highest quality standards across all our manufacturing sites and are committed to maintain global benchmarks,” Lupin Managing Director Nilesh Gupta said.
